{
  "ticker": "LDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969758",
  "id": "02969758",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250716",
  "time": "1011",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv8rhbxv6c4p.pdf",
  "summary": "**Material Information Summary:**  \n\n- **Exclusive U.S. Distribution Agreement:**  \n  - 6-year deal with PHASE Scientific for FebriDx\u00ae; potential total value up to **US$317M (A$487M)** contingent on FDA CLIA waiver and minimum order quantities (MOQs).  \n  - **Upfront payments:**  \n    - **US$1M** exclusivity fee (paid on signing).  \n    - **US$1M** prepaid purchase order (paid on signing).  \n    - **US$1.5M** prepaid order upon FDA CLIA waiver application (expected within 3 months).  \n    - **US$5M** prepaid commitment upon CLIA waiver approval.  \n\n- **CLIA Waiver Progress:**  \n  - **105/120** bacterial-positive patients enrolled in study; completion expected by **August 2025**, FDA submission within ~1 month after.  \n  - If waiver is denied, MOQs reduce to **7%** of original targets (contract value ~**US$25M/A$38M**).  \n\n- **Key Risk/Conditionality:**  \n  - Full contract value hinges on FDA CLIA waiver approval. Gross margins expected to meet/exceed historical levels.  \n\n- **Additional Note:**  \n  - Potential financing agreement under discussion (uncertain at time of announcement).",
  "usage": {
    "prompt_tokens": 2784,
    "completion_tokens": 284,
    "total_tokens": 3068,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T00:57:18.504758"
}